|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Allergan_Aesthetics
gptkb:Trelstar
|
|
gptkbp:acquisition
|
gptkb:Mede_Analytics
gptkb:Medi_Gene_AG
gptkb:Boehringer_Ingelheim's_consumer_health_business
Tercica, Inc.
Biovex Group, Inc.
Oncology Business of Merrimack Pharmaceuticals.
|
|
gptkbp:awards
|
Various industry awards
|
|
gptkbp:ceo
|
gptkb:David_Meek
|
|
gptkbp:clinical_trial
|
Completed
Ongoing
Phase III
|
|
gptkbp:collaborations
|
Academic institutions
Research organizations
|
|
gptkbp:community_engagement
|
Active
|
|
gptkbp:employees
|
over 5,000
~5,000
|
|
gptkbp:founded
|
gptkb:1929
|
|
gptkbp:founder
|
Henri Ipsen
|
|
gptkbp:global_presence
|
gptkb:battle
|
|
gptkbp:headcount
|
Increased in recent years
|
|
gptkbp:headquarters
|
gptkb:Paris,_France
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ipsen
|
|
gptkbp:industry
|
Pharmaceuticals
biopharmaceuticals
|
|
gptkbp:invention
|
Numerous
|
|
gptkbp:investment
|
R& D
|
|
gptkbp:market
|
Global
global
|
|
gptkbp:parent_company
|
Ipsen S. A.
|
|
gptkbp:partnership
|
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
Merck K Ga A
|
|
gptkbp:partnerships
|
gptkb:Eisai_Co.,_Ltd.
|
|
gptkbp:philanthropy
|
Involved in healthcare initiatives
|
|
gptkbp:products
|
Botulinum toxin
oncology drugs
Somatuline
Onivyde
endocrinology drugs
neurotoxin products
|
|
gptkbp:region
|
Worldwide
|
|
gptkbp:research_and_development
|
Significant investment
|
|
gptkbp:research_areas
|
gptkb:healthcare_organization
Neuroscience
Endocrinology
|
|
gptkbp:research_focus
|
Neurodegenerative diseases
oncology
Cancer therapies
Rare diseases
neurotoxins
|
|
gptkbp:revenue
|
over $1 billion
€2.5 billion (2020)
|
|
gptkbp:social_responsibility
|
Active
|
|
gptkbp:stock_exchange
|
gptkb:Euronext_Paris
|
|
gptkbp:subsidiary
|
Ipsen Pharma
Ipsen Biopharmaceuticals
Ipsen Biopharmaceuticals, Inc.
Ipsen S. A. S.
|
|
gptkbp:sustainability_initiatives
|
Implemented
|
|
gptkbp:website
|
www.ipsen.com
|